2m 2m 2m 2m 2m 2m 2m
ALLOGENE THERAP (ALLO)
NASDAQ
$2.01+$0.010 (+0.50%)
Price as of Jun 03, 2026 7:58 PM EDT- $749.0MMarket Cap
- 51.85%1-Year Change
- BiotechnologyIndustry
ALLOGENE THERAP (ALLO)
$2.01+$0.010 (+0.50%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 22,000 -76.84% | 95,000 -39.10% | 156,000 -99.59% | |
Cost of Revenue | 800,000 +14.29% | 700,000 +133.33% | 300,000 N/A | N/A N/A | |
Gross Profit | -800,000 +17.99% | -678,000 +230.73% | -205,000 -231.41% | 156,000 -99.59% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -150.2M -21.92% | -192.3M -20.84% | -242.9M -5.25% | -256.4M +16.45% | |
Depreciation and Amortization Expense | 12.4M -9.38% | 13.6M -3.94% | 14.2M N/A | 0 N/A | |
Total Operating Expenses | 209.3M -23.39% | 273.2M -16.66% | 327.8M -2.34% | 335.7M +14.07% | |
Operating Profit | -209.3M -23.38% | -273.2M -16.64% | -327.7M -2.32% | -335.5M +31.18% | |
Interest Income | 19.3M -4.29% | 20.2M +10.08% | 18.3M +300.94% | 4.6M N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 19.3M -4.29% | 20.2M +10.08% | 18.3M +300.94% | 4.6M N/A | |
Total Nonoperating Income and Expense | 18.4M +14.81% | 16.1M +3,300.85% | 472,000 +109.68% | -4.9M +302.14% | |
Income before Taxes | -190.9M -25.77% | -257.1M -21.54% | -327.7M -2.32% | -335.5M +30.56% | |
Income Taxes | 0 -100.00% | 443,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -190.9M -25.90% | -257.6M -83.51% | -1.6B +26.49% | -1.2B +36.72% | |
Net Income from Continuing Operations Applicable to Common | -190.9M -25.77% | -257.1M -83.54% | -1.6B +26.49% | -1.2B +380.54% | |
Basic EPS and Net Income | -0.87 -34.09% | -1.32 -36.84% | -2.09 -12.18% | -2.38 +25.93% | |
Diluted EPS and Net Income | -0.87 -34.09% | -1.32 -36.84% | -2.09 -12.18% | -2.38 +25.93% | |
Basic Weighted Average Shares | 220.6M +13.25% | 194.8M +24.14% | 156.9M +9.63% | 143.1M +5.39% | |
Diluted Weighted Average Shares | 220.6M +13.25% | 194.8M +24.14% | 156.9M +9.63% | 143.1M +5.39% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 51.7M -31.28% | 75.2M -9.54% | 83.2M +34.33% | 61.9M -64.28% | |
Short-Term Investments | 198.5M -8.62% | 217.3M -40.57% | 365.5M -19.73% | 455.4M +60.36% | |
Cash and Cash Equivalents and Short-Term Investments | 250.2M -14.45% | 292.5M -34.82% | 448.7M -13.27% | 517.3M +13.12% | |
Total Current Assets | 257.7M -15.04% | 303.4M -33.92% | 459.1M -13.18% | 528.8M +12.20% | |
Accumulated Depreciation | 72.5M +15.98% | 62.5M +22.42% | 51.1M +38.50% | 36.9M +57.89% | |
Property and Plant and Equipment and Net | 72.8M -15.36% | 86.1M -13.49% | 99.5M -11.84% | 112.8M -8.25% | |
Total Long-Term Assets | 3.6M +55.48% | 2.3M -64.79% | 6.6M -30.95% | 9.6M +64.47% | |
Total Assets | 415.9M -24.20% | 548.7M -14.64% | 642.8M -21.76% | 821.6M -20.90% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 32.5M -8.47% | 35.5M -4.20% | 37.1M -30.99% | 53.7M +11.53% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 15.8M +103.63% | 7.8M +49.86% | 5.2M -11.42% | 5.8M +41.75% | |
Total Liabilities | 123.4M -2.50% | 126.5M -3.12% | 130.6M -15.57% | 154.7M +26.56% | |
Retained Earnings | -2.0B +10.49% | -1.8B +16.49% | -1.6B +26.50% | -1.2B +36.71% | |
Total Stockholders Equity | 292.5M -30.71% | 422.2M -17.58% | 512.2M -23.19% | 666.9M -27.23% | |
Total Shares Outstanding | 229.4M +8.11% | 212.2M +25.83% | 168.6M +16.76% | 144.4M +1.27% | |
Cash Flow | |||||
Cash from Operating Activities | -149.2M -25.49% | -200.3M -15.75% | -237.7M +7.81% | -220.5M +19.32% | |
Capital Expenditures | 386,000 -44.38% | 694,000 -54.22% | 1.5M -70.80% | 5.2M -75.80% | |
Cash from Investing Activities | 95.6M +26.25% | 75.7M -53.65% | 163.3M +53.82% | 106.2M -35.13% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 30.2M -74.15% | 116.7M +21.92% | 95.7M +3,143.90% | 3.0M -75.34% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | -3,081.82% +1,328.16% | -215.79% N/A | N/A N/A | |
Operating Margin | N/A N/A | -1,241,813.64% +259.96% | -344,986.32% +60.39% | -215,087.18% +32,264.15% | |
Return on Assets | -39.58% -8.46% | -43.24% -79.74% | -213.35% +60.68% | -132.78% +66.58% | |
Return on Equity | -53.42% -3.12% | -55.13% -79.19% | -264.98% +69.85% | -156.00% +72.36% | |
Revenue Growth | -100.00% +30.14% | -76.84% +96.51% | -39.10% -60.74% | -99.59% N/A | |
Current Ratio | 7.93 -7.18% | 8.54 -31.02% | 12.38 +25.80% | 9.84 +0.60% | |
Cash Ratio | 1.59 -24.92% | 2.12 -5.58% | 2.24 +94.64% | 1.15 -67.97% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow